Key result
Antithrombin concentrates linked to ~66% lower in-hospital mortality vs FFP in heparin-resistant bypass patients.
Why the study?
Heparin resistance is a common complication during cardiopulmonary bypass, and this study compared key clinical outcomes between treatment with antithrombin supplementation versus fresh frozen plasma.
Does antithrombin concentrate reduce mortality and ICU length of stay compared to fresh frozen plasma in adult patients with suspected heparin resistance undergoing cardiopulmonary bypass?
Cohort (n=502)
Yes
Does antithrombin concentrate reduce mortality and ICU length of stay compared to fresh frozen plasma in adult patients with suspected heparin resistance undergoing cardiopulmonary bypass?
In a retrospective analysis of cardiopulmonary bypass patients with suspected heparin resistance, antithrombin concentrate was associated with significantly lower mortality compared to fresh frozen plasma.
Answers are grounded in this paper and cite their sources.
May support antithrombin over plasma in heparin-resistant bypass; leaves open confirmation in randomized trials.
Background Heparin resistance is a common complication of surgical patients requiring anticoagulation, such as those undergoing cardiopulmonary bypass (CPB). Treatments to address heparin resistance include supplementation of antithrombin (AT) or fresh frozen plasma (FFP). This retrospective database analysis compared key outcomes in suspected heparin-resistant patients undergoing CPB treated with AT or FFP. Methods De-identified United States electronic health records (Cerner Health Facts®) were queried. International Classification of Diseases (ICD-9/10) codes were used to determine CPB procedures and FFP administration. AT administration was identified using medication data, while a combination of lab and medication data examining activated clotting times detected heparin resistance in FFP patients. Adult inpatients (≥18 years old) seen between 2001 and 2018 were included. Differences in mortality, intensive care unit (ICU) length of stay (LOS), and hospital-free days (using a 30-day post-discharge period) were assessed with univariate models as well as adjusted logistic regression models controlling for patient characteristics and Charlson Comorbidity Index (CCI) scores. Results Of the 502 patients identified, 247 received AT and 255 received FFP. The FFP cohort was associated with a higher CCI compared to the AT cohort (3.3 ± 2.4 vs. 2.3 ± 2.0, P < .001). The AT cohort was associated with a 71% (Odds Ratio [OR]: 0.29, 95% Confidence Interval [CI]: P = .003) and 66% (OR: 0.34, 95% CI: P = .01) reduction in mortality when compared to FFP using univariate and adjusted logistic regression models, respectively. Similarly, use of AT also showed a 22% shorter ICU LOS ( P = .02) and 10% more hospital-free days in the 30 days following discharge ( P = .004) according to the univariate models, though statistical significance was absent within adjusted models in both ICU LOS ( P = .08) and hospital-free days ( P = .53). Conclusions Compared to FFP, AT use suggests a reduction in the odds of mortality in suspected heparin-resistant patients undergoing CPB, though larger prospective studies are necessary to elucidate potential differences in hospital-free days or ICU LOS across treatment modalities.
No takes yet. Share an insight, caveat, or question.
Bader et al. (2023) conducted a cohort in Suspected heparin resistance in patients undergoing cardiopulmonary bypass (CPB) (n=502). Antithrombin (AT) concentrates vs. Fresh frozen plasma (FFP) was evaluated on In-hospital mortality (OR 0.34, 95% CI 0.15-0.80, p=0.01). Antithrombin concentrates were associated with lower in-hospital mortality vs fresh frozen plasma in heparin-resistant cardiopulmonary bypass patients.
Synapse has enriched 10 related papers. Consider them for comparative context: